標(biāo)題: Titlebook: Oncology in the Precision Medicine Era; Value-Based Medicine Ravi Salgia Book 2020 Springer Nature Switzerland AG 2020 oncology.cancer.prec [打印本頁(yè)] 作者: 強(qiáng)烈興趣 時(shí)間: 2025-3-21 18:42
書目名稱Oncology in the Precision Medicine Era影響因子(影響力)
書目名稱Oncology in the Precision Medicine Era影響因子(影響力)學(xué)科排名
書目名稱Oncology in the Precision Medicine Era網(wǎng)絡(luò)公開度
書目名稱Oncology in the Precision Medicine Era網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Oncology in the Precision Medicine Era被引頻次
書目名稱Oncology in the Precision Medicine Era被引頻次學(xué)科排名
書目名稱Oncology in the Precision Medicine Era年度引用
書目名稱Oncology in the Precision Medicine Era年度引用學(xué)科排名
書目名稱Oncology in the Precision Medicine Era讀者反饋
書目名稱Oncology in the Precision Medicine Era讀者反饋學(xué)科排名
作者: 讓步 時(shí)間: 2025-3-21 22:03
Hepatocellular Carcinoma,t genomic profiling of individual patient tumors can provide physicians with insight into the best course of treatment including novel targeted therapies. Increased genomic profiling of patient tumors in the future may contribute to a more effective and individualized approach to the management of HCC.作者: 捐助 時(shí)間: 2025-3-22 00:36 作者: Induction 時(shí)間: 2025-3-22 06:26
Sarcomas,for carcinogenesis of different subtypes of STS and allowed for the increased use of targeted therapies. In this review, we aim to describe the current treatments of STS based on subtype and advancements in molecular diagnostics.作者: 和平主義者 時(shí)間: 2025-3-22 10:15 作者: IST 時(shí)間: 2025-3-22 14:25 作者: Creatinine-Test 時(shí)間: 2025-3-22 17:16
Melanoma,rationale for treatment decisions, and the principles underlying the need to increase our knowledge, provide definition, and judiciously incorporate value-based diagnostic, treatment, and surveillance strategies.作者: 同義聯(lián)想法 時(shí)間: 2025-3-23 00:22 作者: 千篇一律 時(shí)間: 2025-3-23 03:46 作者: –LOUS 時(shí)間: 2025-3-23 08:53 作者: 吹牛需要藝術(shù) 時(shí)間: 2025-3-23 10:37 作者: Directed 時(shí)間: 2025-3-23 17:05 作者: 花費(fèi) 時(shí)間: 2025-3-23 19:30
Healthcare Perspective,treatments are improving the prognosis for many patients. Yet in the midst of this time, there is significant concern about the economic sustainability of delivering this care. Without a coherant value framework, that intergrates meaningful data about patients’ prognosis, goals of care, and therapeu作者: Climate 時(shí)間: 2025-3-23 23:33
Lung Cancer,rs. Treatment with targeted agents for non-small cell lung cancer (NSCLC) and immunotherapy for both NSCLC and small-cell lung cancer (SCLC) are leading to improvement in clinical outcomes for patients. Genomic alterations in NSCLC define distinct subtypes with specific mechanisms leading to tumor g作者: 秘方藥 時(shí)間: 2025-3-24 03:32
Esophageal and Gastric Cancer,, MSI, and PD-L1 tumor biomarkers. The latter two only recently emerged in the past 2?years, and PD-L1 determination still remains imperfect with questions remaining on optimal cutoff levels and if timing of tumor sampling matters with the dynamic nature of activation of immune pathways. Ongoing cli作者: Spina-Bifida 時(shí)間: 2025-3-24 08:10
Sarcomas,e more than 50 different histological subtypes. For most STS subtypes, cytotoxic chemotherapy still remains the principal treatment for advanced and metastatic disease. In the past several decades, our expanding understanding of cancer biology has revealed distinct molecular alterations responsible 作者: 學(xué)術(shù)討論會(huì) 時(shí)間: 2025-3-24 13:28
Multiple Myeloma,iven by genetic changes and alterations in the bone marrow microenvironment. A large disparity in outcomes has been observed; accordingly, disease may be stratified into high and standard risk. Triplet regimens, including bortezomib-lenalidomide-dexamethasone, have become preferred regimens as induc作者: 恫嚇 時(shí)間: 2025-3-24 15:25 作者: 圣人 時(shí)間: 2025-3-24 20:03
Colon Cancer,se from 1?year to nearly 3?years with some of these patients achieving long-term cure. This has been accomplished both by the development of novel agents such as anti-VEGF antibodies and anti-EGFR receptor antibodies and by better selecting the patients who should receive these therapies. This work 作者: 新奇 時(shí)間: 2025-3-25 03:11 作者: 混合,攙雜 時(shí)間: 2025-3-25 06:59
Prostate Cancer,re paradigm can benefit from precision medicine. There is clearly a need to confidently avoid treatment for cancers that are slow growing, provide the optimal treatment to eliminate cancer primarily, and control aggressive disease using personalized treatment goals and regimens. We are moving beyond作者: 等待 時(shí)間: 2025-3-25 09:33 作者: 浮雕寶石 時(shí)間: 2025-3-25 12:59
Molecular Testing in Ovarian Cancer: Recommendations and Treatment Considerations, frequent), endometrioid, and clear cell, mucinous, and low-grade serous carcinomas. Mutations in the tumor suppressor gene TP53, BRCA mutations, and abnormalities of DNA repair genes are found primarily in high-grade serous carcinomas, while mutations in other key molecular pathways such as Ras/Raf作者: 輕快帶來(lái)危險(xiǎn) 時(shí)間: 2025-3-25 19:37
Genomic Cancer Risk Assessment, precision therapy. In this chapter we review the historical context and foundational science of cancer genetics and genomics and describe current approaches and challenges to the translation of genomic information for the practice of precision medicine and prevention. Known hereditary cancer syndro作者: JUST 時(shí)間: 2025-3-25 21:27
Triple-Negative Breast Cancer,r (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER-2). The annual incidence of TNBC is estimated to be approximately 40,000, with 20,000 diagnosed with metastatic disease in the USA (Plasilova et al. Medicine 95:e4614, 2016). The current standard-of-care treatment 作者: invulnerable 時(shí)間: 2025-3-26 01:20 作者: lymphedema 時(shí)間: 2025-3-26 06:16
Digital Patient Engagement and Social Media,e, social media use is boundless, with ever-increasing capabilities and innovations. Popularity of social media use in the general public has increased tremendously. At the same time, there is a parallel increase in social media use by healthcare professionals and healthcare professional organizatio作者: circumvent 時(shí)間: 2025-3-26 12:15 作者: DAMN 時(shí)間: 2025-3-26 14:32 作者: 精密 時(shí)間: 2025-3-26 19:57
Primary Central Nervous System Tumors,nostication, and therapeutic management of primary central nervous system (CNS) tumors. An overview is provided of the major categories of primary CNS tumors and the key tumor subtypes which comprise these categories. With regard to diagnosis, the radiographic and pathologic features are highlighted作者: Tincture 時(shí)間: 2025-3-26 23:00 作者: LAVE 時(shí)間: 2025-3-27 04:14
ract.Written by internationally respected experts in this fiThe book covers all relevant topics of uropathology (tumoral and non-tumoral), from the normal histology of the genitourinary tract to pathological findings of diseases in the male genital and urinary tract. To make the content more accessi作者: 無(wú)法治愈 時(shí)間: 2025-3-27 08:08 作者: effrontery 時(shí)間: 2025-3-27 10:14
Joy Huang,Ashley Abing,Karen L. Reckampndings of diseases in the male genital and urinary tract. To make the content more accessible, all content is arranged alphabetically and each entry is uniformly structured, presenting the epidemiology, the clinical signs, the gross and histological features, the immunohistochemical stainings, and t作者: blister 時(shí)間: 2025-3-27 17:19
Michael J. Jang,Joseph Chaondings of diseases in the male genital and urinary tract. To make the content more accessible, all content is arranged alphabetically and each entry is uniformly structured, presenting the epidemiology, the clinical signs, the gross and histological features, the immunohistochemical stainings, and t作者: 大酒杯 時(shí)間: 2025-3-27 18:57 作者: 證實(shí) 時(shí)間: 2025-3-28 00:27 作者: 離開就切除 時(shí)間: 2025-3-28 06:09 作者: menopause 時(shí)間: 2025-3-28 09:54
Blase Politeeated differently than locally advanced prostate cancer, or prostate cancer with loco-regional extension to the pelvic lymph nodes, or metastatic prostate cancer with extension to the bone or distant lymph nodes or even viscera. The need for staging in a patient might be necessary in several clinica作者: staging 時(shí)間: 2025-3-28 13:24 作者: 綁架 時(shí)間: 2025-3-28 16:18 作者: GLIDE 時(shí)間: 2025-3-28 21:58
Tanya Dorff,Petros Grivas, Latin America and Europe..With the first, the .Asia. volume Prof. Dahlkamp presents a complete uranium-resource reference based on the latest research and also gives access to previously unavailable data. The basic purpose, the presentation of an overview and data of uranium geology, is completed 作者: Outmoded 時(shí)間: 2025-3-28 23:36
Kathy Pan,Mihaela C. Cristea, Latin America and Europe..With the first, the .Asia. volume Prof. Dahlkamp presents a complete uranium-resource reference based on the latest research and also gives access to previously unavailable data. The basic purpose, the presentation of an overview and data of uranium geology, is completed 作者: Mnemonics 時(shí)間: 2025-3-29 05:18 作者: 驕傲 時(shí)間: 2025-3-29 10:59
Ritika Vankina,Yuan Yuan, Latin America and Europe..With the first, the .Asia. volume Prof. Dahlkamp presents a complete uranium-resource reference based on the latest research and also gives access to previously unavailable data. The basic purpose, the presentation of an overview and data of uranium geology, is completed 作者: Fierce 時(shí)間: 2025-3-29 14:26
Kathryn Bollin,Kim Margolinailable in English or in the west.The huge amount of text da.Uranium Deposits of the World., in three volumes, comprises an unprecedented compilation of data and descriptions of the uranium regions in Asia, USA, Latin America and Europe..With the first, the .Asia. volume Prof. Dahlkamp presents a co作者: 使成核 時(shí)間: 2025-3-29 18:22
Virginia Sun, Latin America and Europe..With the first, the .Asia. volume Prof. Dahlkamp presents a complete uranium-resource reference based on the latest research and also gives access to previously unavailable data. The basic purpose, the presentation of an overview and data of uranium geology, is completed 作者: 火車車輪 時(shí)間: 2025-3-29 21:56 作者: 萬(wàn)神殿 時(shí)間: 2025-3-30 03:18
Dan Zhao,Rebecca Pharaon,Erminia Massarelli, Latin America and Europe..With the first, the .Asia. volume Prof. Dahlkamp presents a complete uranium-resource reference based on the latest research and also gives access to previously unavailable data. The basic purpose, the presentation of an overview and data of uranium geology, is completed 作者: 善變 時(shí)間: 2025-3-30 07:44
Rimas V. Lukas,Vinai Gondi,Orin Bloch,Maciej M. Mrugala, Latin America and Europe..With the first, the .Asia. volume Prof. Dahlkamp presents a complete uranium-resource reference based on the latest research and also gives access to previously unavailable data. The basic purpose, the presentation of an overview and data of uranium geology, is completed 作者: Systemic 時(shí)間: 2025-3-30 11:44 作者: ACME 時(shí)間: 2025-3-30 13:00
Lung Cancer,n tumor type, demonstrating molecular connections between diverse tumors. Immunotherapy in lung cancer has also redefined treatment paradigms for patients with lung cancer. Initially, single-agent treatment with programmed death 1 (PD-1) and programmed death receptor ligand 1 (PD-L1) antibodies demo作者: 偏見 時(shí)間: 2025-3-30 20:05
Multiple Myeloma,er tandem transplantations are of significant benefit. Moreover, allogeneic transplantations yield relatively high transplant-related mortality rates and uncertain benefit over ASCT and therefore is not widely performed. In relapsed disease, disease-related, patient-related, and treatment-related pa作者: FUSE 時(shí)間: 2025-3-30 22:48
Colon Cancer,ducing new agents despite several well-done trials conducted in the United States and Europe. We have to revisit as a scientific community the use of the metastatic setting as a predictive environment for the adjuvant setting. We have, however, been able to reduce the intensity of existing therapies作者: Euthyroid 時(shí)間: 2025-3-31 04:08
Genomic Cancer Risk Assessment,gnition of potential germline genomic information in the context of tumor analyses for precision medicine. The scope of knowledge, tools, and expertise required for practitioner-level competence in genomic counseling is summarized and highlights the need for genetics and genomics professional educat作者: 極深 時(shí)間: 2025-3-31 06:37
Triple-Negative Breast Cancer,ents still face increased risk of early metastasis and death from TNBC (Anders and Carey. Clin Breast Cancer 9:S73–S81, 2009). In the metastatic setting following first-line treatment, median overall survival is 6–13?months, and medial progression-free survival (PFS) is 3–4?months (Kassam et al. Cli作者: ironic 時(shí)間: 2025-3-31 11:02
Digital Patient Engagement and Social Media,, research reports, state of the science papers, position papers, and clinical guidelines from professional organizations, the primary purpose of this chapter is to describe the current use of digital patient engagement and social media use in oncology care, and to describe evidence-based informatio作者: 擴(kuò)大 時(shí)間: 2025-3-31 17:12 作者: 內(nèi)部 時(shí)間: 2025-3-31 17:49 作者: 寡頭政治 時(shí)間: 2025-3-31 22:16 作者: 構(gòu)想 時(shí)間: 2025-4-1 01:56 作者: Finasteride 時(shí)間: 2025-4-1 09:07 作者: 砍伐 時(shí)間: 2025-4-1 10:14 作者: BOLT 時(shí)間: 2025-4-1 16:41 作者: Hemodialysis 時(shí)間: 2025-4-1 20:32
Rebecca Allen,Daneng Lind districts, and (c)?detailed characteristics of selected ore fields and deposits. This includes sections on geology, alteration, mineralization, shape and dimensions of deposits, isotopes data, ore control an978-3-540-78558-3作者: GROVE 時(shí)間: 2025-4-2 00:37
